Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Strategic Projects - Group

University of Western Ontario

$113,700.00

Development of a reliable, efficient and economic chiral drug separation process

FY 2007-08

Summary
Chirality is a major concern in the modern pharmaceutical, food and agricultural industries. The sale of chiral drugs is close to one-third of all drug sales worldwide. Ordinary chemical production methods for chiral drugs produce a racemic mixture containing enantiomers having identical chemical compositions but different structural orientations in space. It is quite common to find that one isomeric form has a therapeutic effect on the human body while its enantiomer is harmful or ineffective. Hence, there is obvious benefit from separating the two enantiomers to enhance drug's safety and tolerability. The importance of chirally pure drugs has risen dramatically in recent years due to new FDA regulations requiring that chiral drugs be as pure as possible containing a single pure enantiomer.The present research initiative aims to develop reliable, efficient and economic separation routes for industry not only in the early development step of new pharmaceuticals but also in large-scale preparation stage. Specifically, two approaches will be explored: (a) crystallization via diastereomeric salt formation, and (b) hybrid simulated moving bed (SMB) and crystallization process. In the latter approach, a SMB will be used first for enantiomer enrichment beyond the eutectic composition of the SLE diagram followed by direct crystallization to recover pure single enantiomers. Another unique feature of this research work will be to apply the concept of multi-objective optimization in the innovative design and development of the two processes. At current stage it is difficult to foretell which process approach will be cost-effective as SMB requires costly chiral stationary phase while crystallization of diastereomeric salts consumes expensive resolving agent. The techniques to be developed in this research will be generic and could be applied to most chiral systems in the various industries such as food, pharmaceuticals and agricultural. This research would lead to a successful clean and cost-effective processing technology that would create value-added products in the rapidly changing global economy.
Program
Strategic Projects - Group
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
350490-2007
Name nom
Rohani, Sohrab
Department département
Chemical and Biochemical Engineering
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2007
Award amount
113700
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1043
Committee name en
Strategic Projects Selection Panel - Manufacturing
Committee name fr
Comité de sélection des projets stratégiques - Fabrication
Area of application code
602
Area of application group en
Construction, urban and rural planning
Area of application group fr
Construction, urbanisme et aménagement rural
Area of application en
Materials performance
Area of application fr
Performance des matériaux
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
3
Application title
Development of a reliable, efficient and economic chiral drug separation process
Keyword
NA
Application summary
Chirality is a major concern in the modern pharmaceutical, food and agricultural industries. The sale of chiral drugs is close to one-third of all drug sales worldwide. Ordinary chemical production methods for chiral drugs produce a racemic mixture containing enantiomers having identical chemical compositions but different structural orientations in space. It is quite common to find that one isomeric form has a therapeutic effect on the human body while its enantiomer is harmful or ineffective. Hence, there is obvious benefit from separating the two enantiomers to enhance drug's safety and tolerability. The importance of chirally pure drugs has risen dramatically in recent years due to new FDA regulations requiring that chiral drugs be as pure as possible containing a single pure enantiomer.The present research initiative aims to develop reliable, efficient and economic separation routes for industry not only in the early development step of new pharmaceuticals but also in large-scale preparation stage. Specifically, two approaches will be explored: (a) crystallization via diastereomeric salt formation, and (b) hybrid simulated moving bed (SMB) and crystallization process. In the latter approach, a SMB will be used first for enantiomer enrichment beyond the eutectic composition of the SLE diagram followed by direct crystallization to recover pure single enantiomers. Another unique feature of this research work will be to apply the concept of multi-objective optimization in the innovative design and development of the two processes. At current stage it is difficult to foretell which process approach will be cost-effective as SMB requires costly chiral stationary phase while crystallization of diastereomeric salts consumes expensive resolving agent. The techniques to be developed in this research will be generic and could be applied to most chiral systems in the various industries such as food, pharmaceuticals and agricultural. This research would lead to a successful clean and cost-effective processing technology that would create value-added products in the rapidly changing global economy.